News

Google’s New AI Technology May Revolutionize Cancer Treatment

The AI model, called AlphaProteo, can design targeted protein binders, promising breakthroughs in cancer treatments and diseases like diabetes.

Published

4 months ago

September 10, 2024

Nour Nasir

google's new ai technology may revolutionize cancer treatment

Google DeepMind

Proteins are integral to many biological processes within the human body. They play a crucial role in our immune system, helping us to fend off diseases and maintain overall health.

Until now, developing protein molecules for medical purposes has been a time-consuming, expensive, and complex process. However, advancements in artificial intelligence have significantly improved the process, making it more efficient and accessible.

Recently, Google DeepMind researchers introduced a cutting-edge AI-powered model that can create protein binders targeting specific proteins. The groundbreaking development allows scientists to design custom protein molecules that specifically target only cancerous cells while minimizing harm to healthy ones. Hopefully, this will lead to more effective and less harmful treatments for cancer patients.

The newly developed AI model, known as AlphaProteo, also promises to be a game-changer in the diagnosis and treatment of various diseases, including autoimmune disorders like rheumatoid arthritis, and chronic illnesses such as diabetes.

This isn’t Google DeepMind’s first foray into using AI for protein research. In 2021, the company launched AlphaFold, another AI-powered system aimed at predicting the structure of proteins. AlphaProteo builds upon this foundation, further advancing AI’s role in medical research.

Also Read: Tumor-Fighting Nanobots Could Revolutionize Cancer Treatment

The system’s training involved large datasets from the Protein Data Bank and insights from Google’s previous AI research. By leveraging this wealth of data, AlphaProteo avoids the need for traditional, resource-intensive testing methods, saving both time and money.

One of the most significant achievements during AlphaProteo’s testing phase was the strength of the protein binders it produced. On average, these binders were ten times more effective than current designs. The research also included testing protein binders for various target molecules, including those related to diseases like COVID-19 and leukemia.

Related Topics:Artificial Intelligence Google HealthTech

Up Next

6 Arab Musicians Triumph In TikTok MENA LIVE’s #GimmeTheMic

Don't Miss

Key Product Announcements From Apple’s iPhone 16 Event

Click to comment

News

Cemplicity Is Bringing Real-Time Patient Insights To The UAE

The advanced healthcare platform offers tools for chronic disease management and improved patient experiences.

Published

9 hours ago

January 13, 2025

Nour Nasir

Cemplicity

Cemplicity — a leading health-tech company founded in 2013 — has launched its advanced platform in the UAE, aiming to revolutionize patient care and streamline healthcare operations to improve clinical outcomes.

Designed to analyze patient-reported data in real-time, the platform incorporates Patient-Reported Experience Measures (PREMs) and Patient-Reported Outcome Measures (PROMs) to collect and analyze patient feedback. By transforming the data into actionable insights, healthcare providers will be better equipped to improve quality of care and increase efficiency.

Cemplicity’s technology can even tackle chronic conditions like diabetes, which affects 12.3% of the UAE population. By enabling regular symptom tracking and side-effect monitoring (even when patients are at home) the platform ensures proactive care management, and can also optimize early detection and screening of cancers.

Blaik Wilson, Cemplicity’s CEO, shared: “We are excited to bring Cemplicity to the UAE, a nation committed to healthcare excellence. With the private healthcare sector evolving at an impressive pace, partnering with such forward-thinking providers enables us to transform patient feedback into meaningful insights that enhance patient experiences and improve outcomes”.

Wilson added: “Globally, healthcare produces 30% of the world’s data volume. Aggregating and anonymizing patient-reported data not only uncovers trends and evaluates treatment outcomes but also advances the UAE’s broader ambition to lead in medical research and innovation”.

Also Read: Malak Trabelsi Loeb On Leadership And QIS 2025

With a presence in nine countries and partnerships with major healthcare providers like the UK’s National Health Service (NHS), Cemplicity has already redefined how hospitals and clinics leverage patient feedback. Its tools, known for achieving high survey response rates, help link patient experiences to organizational KPIs and Net Promoter Scores (NPS), enabling measurable improvements in operations, and clinical outcomes, while fostering a culture of continuous improvement.

For the UAE market, the platform has been specially adapted to local needs, offering multilingual support (including Arabic) and seamless integration with tools such as WhatsApp and various hospital management systems.